Market Closed -
Nyse
01:40:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
1.1
USD
|
-0.90%
|
|
0.00%
|
+7.84%
|
Fiscal Period: June |
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18.42
|
53.38
|
21.72
|
13.42
|
12.96
|
-
|
-
|
Enterprise Value (EV)
1 |
18.42
|
53.38
|
21.72
|
13.42
|
12.96
|
12.96
|
12.96
|
P/E ratio
|
-2
x
|
-5.73
x
|
-2.69
x
|
-1.55
x
|
-1.51
x
|
-0.99
x
|
-1.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
4.32
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
4.32
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-2.31
x
|
-1.49
x
|
-2.54
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-43.2%
|
-67.1%
|
-39.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,837
|
11,505
|
11,554
|
11,666
|
11,779
|
-
|
-
|
Reference price
2 |
4.800
|
4.640
|
1.880
|
1.150
|
1.100
|
1.100
|
1.100
|
Announcement Date
|
23/08/19
|
12/10/21
|
13/10/22
|
13/10/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.66
|
-
|
-
|
-8.943
|
-8.9
|
-15.1
|
-8.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-293.33%
|
Earnings before Tax (EBT)
1 |
-8.424
|
-
|
-
|
-8.589
|
-8.7
|
-14.8
|
-8.4
|
Net income
1 |
-8.424
|
-8.822
|
-
|
-8.589
|
-8.7
|
-14.8
|
-8.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-280%
|
EPS
2 |
-2.400
|
-0.8100
|
-0.7000
|
-0.7400
|
-0.7300
|
-1.110
|
-0.5700
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-5.6
|
-8.7
|
-5.1
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-170%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/08/19
|
12/10/21
|
13/10/22
|
13/10/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-1.788
|
-1.793
|
-1.622
|
-
|
-
|
-
|
-2.185
|
-2.3
|
-2.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-1.793
|
-1.78
|
-1.571
|
-
|
-
|
-
|
-2.115
|
-2.2
|
-2.3
|
Net income
1 |
-2.613
|
-1.793
|
-1.78
|
-1.571
|
-
|
-
|
-1.969
|
-2.115
|
-2.2
|
-2.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2300
|
-0.1600
|
-0.1500
|
-0.1400
|
-0.1500
|
-0.1500
|
-0.1700
|
-0.1800
|
-0.1900
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
16/05/22
|
13/10/22
|
14/11/22
|
14/02/23
|
15/05/23
|
14/11/23
|
14/02/24
|
-
|
-
|
Fiscal Period: June |
2019
|
2021
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-5.6
|
-8.7
|
-5.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/08/19
|
12/10/21
|
13/10/23
|
-
|
-
|
-
|
Average target price
6.5
USD Spread / Average Target +490.91% Consensus |
1st Jan change
|
Capi.
|
---|
| +7.84% | 12.96M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|